Illumina, Inc. (NASDAQ:ILMN) Receives Average Rating of “Hold” from Brokerages

Shares of Illumina, Inc. (NASDAQ:ILMN) have been given an average rating of “Hold” by the sixteen research firms that are presently covering the stock, Marketbeat.com reports. Two investment analysts have rated the stock with a sell recommendation, six have issued a hold recommendation and eight have issued a buy recommendation on the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $236.05.

A number of research firms have recently commented on ILMN. Citigroup reduced their price target on shares of Illumina from $180.00 to $150.00 and set a “sell” rating for the company in a research report on Thursday, August 10th. Stifel Nicolaus reduced their price target on shares of Illumina from $265.00 to $225.00 and set a “buy” rating for the company in a research report on Thursday, August 10th. Evercore ISI restated an “outperform” rating and set a $240.00 price target on shares of Illumina in a research report on Friday, September 1st. StockNews.com began coverage on shares of Illumina in a research report on Thursday, August 17th. They set a “hold” rating for the company. Finally, UBS Group reduced their price target on shares of Illumina from $240.00 to $230.00 and set a “neutral” rating for the company in a research report on Tuesday, August 8th.

Insiders Place Their Bets

In other Illumina news, SVP Susan H. Tousi sold 500 shares of the business’s stock in a transaction on Monday, July 24th. The shares were sold at an average price of $190.08, for a total value of $95,040.00. Following the completion of the sale, the senior vice president now directly owns 46,022 shares of the company’s stock, valued at $8,747,861.76. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders sold 1,500 shares of company stock valued at $278,560 over the last three months. Insiders own 0.13% of the company’s stock.

Hedge Funds Weigh In On Illumina

Hedge funds and other institutional investors have recently modified their holdings of the company. Elequin Securities LLC bought a new position in shares of Illumina during the fourth quarter valued at about $29,000. State of Wyoming purchased a new position in shares of Illumina during the second quarter valued at about $32,000. HighMark Wealth Management LLC purchased a new position in shares of Illumina during the first quarter valued at about $33,000. Harel Insurance Investments & Financial Services Ltd. purchased a new position in shares of Illumina during the first quarter valued at about $33,000. Finally, ST Germain D J Co. Inc. purchased a new position in shares of Illumina during the second quarter valued at about $36,000. 92.17% of the stock is owned by institutional investors.

Illumina Stock Down 0.7 %

Illumina stock opened at $158.85 on Friday. Illumina has a 1-year low of $156.14 and a 1-year high of $248.87. The firm has a market capitalization of $25.15 billion, a price-to-earnings ratio of -5.97, a P/E/G ratio of 8.61 and a beta of 1.12. The company has a current ratio of 1.40, a quick ratio of 1.13 and a debt-to-equity ratio of 0.23. The firm has a 50 day simple moving average of $178.63 and a 200 day simple moving average of $199.17.

Illumina (NASDAQ:ILMN) last released its quarterly earnings data on Wednesday, August 9th. The life sciences company reported $0.32 earnings per share for the quarter, beating analysts’ consensus estimates of $0.02 by $0.30. Illumina had a negative net margin of 93.86% and a positive return on equity of 1.97%. The business had revenue of $1.18 billion during the quarter, compared to analyst estimates of $1.16 billion. During the same period in the previous year, the business earned $0.57 EPS. Illumina’s revenue was up 1.2% compared to the same quarter last year. On average, analysts predict that Illumina will post 0.83 earnings per share for the current year.

Illumina Company Profile

Illumina, Inc develops, manufactures, and markets life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; and whole-genome sequencing kits, which sequence entire genomes of any size and complexity, and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.